| Literature DB >> 31788566 |
Pallavi Surana1, Ashwin Kumar Jainarayanan2,3, Nithishwer Mouroug Anand2, Mukta Sharma3.
Abstract
Tuberculosis is a bacterial disease caused by Mycobacterium tuberculosis. It is known to be the second-largest cause of death and models a severe risk to public health throughout the world. Though it affects people of almost every age, individuals with weakened immune systems, (e.g., HIV infection) are more likely to get infected. The present study deals with analyzing non-synonymous mutations in anti-tuberculosis drugs, which may have a significant role in causing XDR and MDR tuberculosis drug resistance. Continued use of tuberculosis drugs, discontinuation of medicines and various other factors can promote drug resistance in the host's body. To understand the actual cause of resistance, we have identified some patterns of mutations which might be responsible for a change in the structure of the protein, ultimately causing drug resistance. Here, we aim to present some of the unique mutation patterns in the genes associated with the marketed drugs that might have a deleterious effect. In this study, we have used molecular docking approach for understanding the ligand binding affinity of the mutated drugs. The results are further validated by molecular dynamics studies.Entities:
Keywords: MDR; Molecular docking; Molecular dynamics; Non-synonymous mutations; Tuberculosis; XDR
Year: 2019 PMID: 31788566 PMCID: PMC6880092 DOI: 10.1016/j.jctube.2019.100124
Source DB: PubMed Journal: J Clin Tuberc Other Mycobact Dis ISSN: 2405-5794
List of known antibiotics their corresponding targets, functions, and PDB ID.
| S. No | Generic name of the marketed drugs | Gene involved | Functions involved | PDB ID |
|---|---|---|---|---|
| 1 | Cycloserine | alr | Catalyzes the interconversion of | 1XFC |
| 2 | Capreomycin | gid | Involved in transferring sugar moieties to the substrates involved | 3CKJ |
| 3 | Amikacin | sirR | Sulfite reductase catalyzes the six-electron reduction of sulfite to sulfide | 5IEB |
| 4 | Streptomycin | rpsL | A homodimer enzyme with two catalytic centers at the dimer interface. The binding after the mutation of substrate-specifying residues is altered by this enzyme | 4G3N |
| 5 | Moxifloxacin | gyrA | Controls and helps the enzyme in DNA recognition | 4HTR |
Interaction analysis, total binding energies and the variation effects of the marketed drugs.
| S. No | Drug | Gene ID | Global energy of docked model (kcal/mol) | PROVEAN (deleterious: neutral) | Interaction Diagram for the best-docked molecule |
|---|---|---|---|---|---|
| 1 | Cycloserine | 1.50 | 16: 08 | ||
| 2 | Capreomycin | −30.41 | 25: 04 | ||
| 3 | Amikacin | −11.14 | 10: 08 | ||
| 4 | Streptomycin | −26.54 | 09: 0 | ||
| 5 | Moxifloxacin | 3.92 | 17: 10 |
Fig. 1Plot of the results from PROVEAN and calculation of the Coefficient of determination (R2).
Fig. 2The RMSD plot of ALR gene *(Other RMSD plots in Supplementary data 1).
Fig. 3The RMSF plot of ALR gene *(Other RMSD plots in Supplementary data 2).
Fig. 4The energy plot of ALR gene *(Other energy plots in Supplementary data 3).
Fig. 5The Hydrogen bonds plot of ALR gene *(Other energy plots in Supplementary data 4).
Statistical analysis for the MD simulations trajectory of wild and mutated proteins.
Fig. 6The radius of gyration plot of ALR gene *(Other energy plots in Supplementary data 5) *(Visualization of the protein superimposed of pre (Green) and post (Red) MD structures can be viewed in Supplementary data 6).